Nektar Therapeutics

Nektar Therapeutics is a clinical-stage biotechnology company pioneering novel immunomodulatory therapies designed to redefine treatment paradigms for autoimmune and inflammatory diseases. The company leverages proprietary IL-2 pathway agonist technology to selectively expand regulatory T cells, targeting the root cause of immune dysregulation rather than symptomatic relief. With a strong track record of successful global partnerships and commercially approved medicines, Nektar is advancing first-in-class therapeutic candidates through Phase 2b clinical trials.